In Canada, the current recommended first-line (1L) treatment for advanced cEGFRm NSCLC is an EGFR TKI, with osimertinib (3rd generation TKI) preferred over 1st generation (gefitinib, erlotinib) and 2nd generation (afatinib) EGFR TKIs based on its superior overall survival benefit vs. comparator EGFR TKIs in the Phase III FLAURA trial and vs. platinum therapy plus pemetrexed in the Phase III AURA3 trial [11,12,13]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.